Walgreens Boots Alliance — Q3 2020 Earnings Presentation
35 slides from Walgreens Boots Alliance's earnings presentation, Jul 9, 2020
Slide 1: Fiscal 2020 Third Quarter Results
Fiscal 2020 Third Quarter Results July 9, 2020
Slide 2: Safe harbor and non-GAAP
Safe harbor and non-GAAP Cautionary Note Regarding Forward-Looking Statements: Cautionary Note Regarding Forward-Looking Statements: All statements in these materials and the related presentation that are not historical including, without limitation, estimates of and goals for future tax, financial
Slide 3: WBA's Critical Role during Global Pandemic
WBA’s Critical Role during Global Pandemic Yahoo! Finance Reuters Mobi Health News Walgreens adopts new measures to fight against BRIEF -Walgreens Boots Alliance to waive Boots UK to connect patients and coronavirus delivery fees for all eligible prescriptions during pharmacists via LIVI Covid-19 si
Slide 4: 3Q financial highlights
3Q financial highlights • GAAP EPS loss of -$1.95 versus EPS of $1.13 in prior year − Boots non-cash impairment charges • Adjusted EPS $0.83 versus $1.47 in prior year, -43.4% in constant currency − estimated COVID-19 impact of -61 to -65 cents • RPU scripts slowed, but delivered continued good comp
Slide 5: COVID-19 had significant impact on 3Q financials
COVID-19 had significant impact on 3Q financials Walgreens Boots UK & Opticians • Rx comp scripts +0.4% from +4.9% in 2Q, fewer • Retail comp store sales -48%, sharp drop in high physician/hospital visits street footfall, peaked at -85% in April; 112 stores temporarily closed • Retail comparable sto
Slide 6: 3Q financial highlights
3Q financial highlights Reported currency Constant currency 3Q20 Δ vs. 3Q19 Δ vs. 3Q19 $ in millions (except EPS and % change) Sales $34,631 + 0.1% + 1.2% Operating income: GAAP -$1,584 - 231.7% Adjusted $919 - 46.5% - 46.4% Net earnings: GAAP -$1,708 - 266.6% Adjusted $723 - 45.9% - 45.6% EPS: GAAP
Slide 7: Year-to-date FY20 financial highlights
Year-to-date FY20 financial highlights Reported currency Constant currency YTD20 Δ vs. YTD19 Δ vs. YTD19 $ in millions (except EPS and % change) Sales $104,791 + 1.8% + 2.5% Operating income: GAAP $662 - 83.9% Adjusted $4,085 - 24.1% - 24.1% Net earnings: GAAP $83 - 97.5% Adjusted $3,288 - 22.6% - 2
Slide 8: Retail Pharmacy USA – financials
Retail Pharmacy USA – financials $ in millions (except %) 3Q20 Δ vs. 3Q19 YTD20 Δ vs. YTD19 Sales $27,357 +3.2% $80,734 +2.9% Adj. gross profit $5,354 - 8.7% $16,976 - 5.7% Adj. SG&A % of sales 16.7% 0.6% 17.0% 0.7% Adj. operating margin 2.9% - 2.0%p 4.0% - 1.3%p Adj. operating income $792 - 38.4% $
Slide 9: Retail Pharmacy USA – pharmacy
Retail Pharmacy USA – pharmacy Comparable 2Q 3Q Pharmacy sales + 3.7% + 3.5% Prescriptions + 4.9% + 0.4% • 3Q Rx comp scripts up +0.4%, lower than 2Q pre-pandemic level of +4.9% − March pull forward in prescription demand from pre-authorizations − April & May lower new prescription starts / lower ph
Slide 10: Retail Pharmacy USA – retail
Retail Pharmacy USA – retail Comparable 2Q 3Q Comp sales + 0.6% + 1.9% Store gross margin + 95bps - 80bps • 3Q retail comp sales up +1.9%, sequential quarterly improvement − gains in Health & Wellness category including PPE & Vitamins +9%, Personal Care +5%, Grocery +8%; offset by discretionary Beau
Slide 11: Retail Pharmacy International – financials
Retail Pharmacy International – financials Constant currency Constant currency $ in millions (except %) 3Q20 Δ vs. 3Q19 YTD20 Δ vs. YTD19 Sales $1,903 - 26.2% $7,704 - 9.8% Adj. operating margin - 7.5% - 13.3%p 1.7% - 4.7%p Adj. operating income - $143 - 191.8% $133 - 77.5% Boots UK comp. pharmacy s
Slide 12: Boots UK – financials
Boots UK – financials Comparable 2Q 3Q Pharmacy sales + 1.8% - 1.0% Retail sales - 4.6% - 48.0% Retail adj. GM % - 65bps - 440bps • March slight pull forward of Rx volume, Rx services sales -65% in both April & May • Retail sales significantly impacted, Boots is not a weekly grocery shopping trip −
Slide 13: Pharmaceutical Wholesale – financials
Pharmaceutical Wholesale – financials Constant currency Constant currency $ in millions (except %) 3Q20 Δ vs. 3Q19 YTD20 Δ vs. YTD19 Sales $5,899 +5.3% $17,971 +7.2% Adj. operating margin 2.3% - 0.2%p 2.2% - 0.2%p Adj. operating income $271 + 5.1% $735 + 5.1% • Continued strong sales growth led by U
Slide 14: Cash flow
Cash flow $ in millions YTD20 Δ vs. YTD19 Operating cash flow $3,398 $183 Cash capital expenditure - $962 $284 Free cash flow $2,436 $467 • YTD free cash flow grew +24% versus prior year • Took proactive action in 3Q to increase our short-term financial flexibility by $5.1bn • Increased dividend for
Slide 15: Transformational Cost Management Program
Transformational Cost Management Program Increasing savings target to in excess of $2.0 billion in annual cost savings by FY22 • Store closures: U.S. 169 closed of 200 planned, Boots UK 76 closed of 200 planned • On target to complete transition of majority of IT Run and Operational Services to TCS
Slide 16: Fiscal year 2020 guidance
Fiscal year 2020 guidance Company introduced full year adj. EPS guidance: $4.65-$4.75 • FY20 COVID-19 impact estimated at -$1.03 to -$1.14 − some improvement in sales trends but uncertain outlook; UK footfall remains very weak − margins will remain under pressure until foot traffic recovers (U.S. re
Slide 17: Financial summary
Financial summary • Significant 3Q impact from COVID-19: estimated -61 to -65 cents • Introducing FY20 adj. EPS guidance of $4.65 to $4.75, COVID-19 impact -$1.03 to -$1.14 − trends improving but nature and duration of recovery uncertain − continued adverse COVID-19 impact in 4Q, especially in UK •
Slide 18: Retail Pharmacy USA
Retail Pharmacy USA © 2020 Walgreens Boots Alliance, Inc. All rights reserved. Refer to safe harbor and non-GAAP on page 2 and endnotes on page 24 18
Slide 19: Retail Pharmacy USA – initiatives
Retail Pharmacy USA – initiatives Create neighborhood health destinations around more modern pharmacy • Village Medical at Walgreens integrated primary care & pharmacy model − better health outcomes − reduce costs − differentiated patient experience • 500-700 co-locations in >30 markets within five
Slide 20: Retail Pharmacy USA – initiatives
Retail Pharmacy USA – initiatives Accelerate digitalization • Establishing marketing and technology platform with Microsoft & new partner Adobe − enhancing digital experience to deliver personalized healthcare & shopping offerings • Mass personalization 3Q retail sales lift +95bps • Total digitally
Slide 21: Retail Pharmacy USA – initiatives
Retail Pharmacy USA – initiatives Transform and restructure retail offering • Providing pharmacy & retail value to customers with new products and services − extending home delivery & drive thru local convenience to ~7,300 locations − building new PPE category to meet customer demands • Advancing ou
Slide 22: Retail Pharmacy International – initiatives
Retail Pharmacy International – initiatives Taking swift and decisive actions to recover from COVID-19 • Announced program to restructure Boots: over 4,000 positions or 7% of the workforce • Playing a key role in supporting the NHS with testing; 31 active sites, 330k tests • Immediately shifted Boot
Slide 23: Refer to safe harbor and non-GAAP on page 2 and endnotes on page 24
© 2020 Walgreens Boots Alliance, Inc. All rights reserved. Refer to safe harbor and non-GAAP on page 2 and endnotes on page 24 23
Slide 24: Endnotes
Endnotes • Please see appendix for reconciliations of non-GAAP financial measures and related disclosures ◦ The company presents certain information related to current period operating results in “constant currency,” which is a non-GAAP financial measure. These amounts are calculated by translating
Slide 25: Appendix
Appendix The information on the following pages provides reconciliations of the supplemental non-GAAP financial measures, as defined under SEC rules, presented in this presentation to the most directly comparable financial measures calculated and presented in accordance with generally accepted accou
Slide 26: Reconciliation of Non-GAAP financial measures
Reconciliation of Non-GAAP financial measures Walgreens Boots Alliance, Inc. and Subsidiaries Supplemental Information (unaudited) (in millions) NET EARNINGS (LOSS) Three months ended May 31, Change vs. 3Q19 Nine months ended May 31, Change vs. FY19 2020 2019 Amount Percent 2020 2019 Amount Percent
Slide 27: Reconciliation of Non-GAAP financial measures
Reconciliation of Non-GAAP financial measures Walgreens Boots Alliance, Inc. and Subsidiaries Supplemental Information (unaudited) DILUTED NET EARNINGS (LOSS) PER SHARE Three months ended May 31, Change vs. 3Q19 Nine months ended May 31, Change vs. FY19 2020 2019 Amount Percent 2020 2019 Amount Perc
Slide 28: Reconciliation of Non-GAAP financial measures
Reconciliation of Non-GAAP financial measures Walgreens Boots Alliance, Inc. and Subsidiaries Supplemental Information (unaudited) (in millions) Three months ended May 31, 2020 Retail Pharmacy Pharmaceutical Walgreens Boots Retail Pharmacy USA International Wholesale1 Eliminations Alliance, Inc. Sal
Slide 29: Reconciliation of Non-GAAP financial measures
Reconciliation of Non-GAAP financial measures Walgreens Boots Alliance, Inc. and Subsidiaries Supplemental Information (unaudited) (in millions) Three months ended May 31, 2019 Retail Pharmacy Pharmaceutical Walgreens Boots Retail Pharmacy USA International Wholesale1 Eliminations Alliance, Inc. Sal
Slide 30: Reconciliation of Non-GAAP financial measures
Reconciliation of Non-GAAP financial measures Walgreens Boots Alliance, Inc. and Subsidiaries Supplemental Information (unaudited) (in millions) Nine months ended May 31, 2020 Retail Pharmacy Pharmaceutical Walgreens Boots Retail Pharmacy USA International Wholesale1 Eliminations Alliance, Inc. Sale
Slide 31: Reconciliation of Non-GAAP financial measures
Reconciliation of Non-GAAP financial measures Walgreens Boots Alliance, Inc. and Subsidiaries Supplemental Information (unaudited) (in millions) Nine months ended May 31, 2019 Retail Pharmacy Pharmaceutical Walgreens Boots Retail Pharmacy USA International Wholesale1 Eliminations Alliance, Inc. Sale
Slide 32: Reconciliation of Non-GAAP financial measures
Reconciliation of Non-GAAP financial measures Walgreens Boots Alliance, Inc. and Subsidiaries Supplemental Information (unaudited) (in millions) EQUITY EARNINGS IN AMERISOURCEBERGEN Three months ended May 31, Nine months ended May 31, 2020 2019 2020 2019 Equity earnings (loss) in AmerisourceBergen (
Slide 33: Reconciliation of Non-GAAP financial measures
Reconciliation of Non-GAAP financial measures Walgreens Boots Alliance, Inc. and Subsidiaries Supplemental Information (unaudited) (in millions) ADJUSTED EFFECTIVE TAX RATE Three months ended May 31, 2020 Three months ended May 31, 2019 Earnings before Earnings before income tax Income tax Effective
Slide 34: Reconciliation of Non-GAAP financial measures
Reconciliation of Non-GAAP financial measures Walgreens Boots Alliance, Inc. and Subsidiaries Supplemental Information (unaudited) (in millions) FREE CASH FLOW Three months ended May 31, Nine months ended May 31, 2020 2019 2020 2019 Net cash provided by operating activities (GAAP) $ 914 $ 2,021 $ 3,
Slide 35: Currency sensitivity
Currency sensitivity Exchange Rates/Impact FY19 Mar '20 Sensitivity Jun '20 Sensitivity GBP/USD 1.28 1.26 1.27 EUR/USD 1.13 1.10 1.11 TRY/USD 0.18 0.16 0.16 Fx Sales Impact vs. FY19 ~($925m)/~(0.7%) ~($880m)/~(0.6%) Fx Adj. Operating Income Impact vs. FY19 ~($15m)/~(0.2%) ~($5m)/~(0.2%) Fx Adj. EPS
Walgreens Boots Alliance — Q3 2020 Earnings Presentation on 6ix